Scientific Reports (Nov 2022)

ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation

  • Adam Sheriff,
  • Ina Guri,
  • Paulina Zebrowska,
  • Virginia Llopis-Hernandez,
  • Imogen R. Brooks,
  • Stavroula Tekkela,
  • Kavita Subramaniam,
  • Ruta Gebrezgabher,
  • Gaetano Naso,
  • Anastasia Petrova,
  • Katarzyna Balon,
  • Alexandros Onoufriadis,
  • Dorota Kujawa,
  • Martyna Kotulska,
  • Gregory Newby,
  • Łukasz Łaczmański,
  • David R. Liu,
  • John A. McGrath,
  • Joanna Jacków

DOI
https://doi.org/10.1038/s41598-022-24184-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Base editing introduces precise single-nucleotide edits in genomic DNA and has the potential to treat genetic diseases such as the blistering skin disease recessive dystrophic epidermolysis bullosa (RDEB), which is characterized by mutations in the COL7A1 gene and type VII collagen (C7) deficiency. Adenine base editors (ABEs) convert A-T base pairs to G-C base pairs without requiring double-stranded DNA breaks or donor DNA templates. Here, we use ABE8e, a recently evolved ABE, to correct primary RDEB patient fibroblasts harboring the recurrent RDEB nonsense mutation c.5047 C > T (p.Arg1683Ter) in exon 54 of COL7A1 and use a next generation sequencing workflow to interrogate post-treatment outcomes. Electroporation of ABE8e mRNA into a bulk population of RDEB patient fibroblasts resulted in remarkably efficient (94.6%) correction of the pathogenic allele, restoring COL7A1 mRNA and expression of C7 protein in western blots and in 3D skin constructs. Off-target DNA analysis did not detect off-target editing in treated patient-derived fibroblasts and there was no detectable increase in A-to-I changes in the RNA. Taken together, we have established a highly efficient pipeline for gene correction in primary fibroblasts with a favorable safety profile. This work lays a foundation for developing therapies for RDEB patients using ex vivo or in vivo base editing strategies.